Who
Alexandra Glucksmann
Director
Company insider
Files Form 4 as: Director, Regenxbio; Chief Operating Officer, Editas Medicine.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $170K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 23 Aug 2016
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,815 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —7,768 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —24,454 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —4,790 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,892 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —3,486 at $0.00 | filing |
| 3 Jun 2022filed 7 Jun 2022 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —15,324 at $0.00 | filing |
| 3 Jun 2022filed 7 Jun 2022 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —3,010 at $0.00 | filing |
| 4 Jun 2021filed 8 Jun 2021 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 29 May 2020filed 2 Jun 2020 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 31 May 2019filed 4 Jun 2019 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 May 2018filed 30 May 2018 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Mar 2017filed 17 Mar 2017 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Code M | $6501,000 at $0.65 | filing |
| 15 Mar 2017filed 17 Mar 2017 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Sold | $26K1,000 at $26.41 | filing |
| 15 Mar 2017filed 17 Mar 2017 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 15 Feb 2017filed 16 Feb 2017 | EDIT Editas MedicineGenomics & Gene Editing | SEC FORM 4 Code M | $3,9006,000 at $0.65 | filing |
News
Financial Contrast: Alvotech (NASDAQ:ALVO) & Editas Medicine (NASDAQ:EDIT)EDIT · themarketsdaily.com · 18 Oct 2026Editas Medicine (NASDAQ:EDIT) Raised to Overweight at Wells Fargo & CompanyEDIT · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Alexandra Glucksmann; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.